Pediatric COVID-19 Dashboard and Clinical Phenotypes

儿科 COVID-19 仪表板和临床表型

基本信息

  • 批准号:
    10658654
  • 负责人:
  • 金额:
    $ 23.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Pediatric COVID-19 is a major national and global public health problem. SARS-CoV-2 causes two types of severe pediatric disease: acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C). Both acute COVID-19 and MIS-C can cause organ dysfunction and death. Children have typically experienced milder COVID-19 illness severity than adults. However, during pandemic surges caused by the delta and omicron variants of SARS-CoV-2, pediatric health systems struggled to support the needs of their communities and regions. Periods of peak hospital demand were also driven by simultaneous mental health crises, staffing challenges, and off-cycle transmission of viruses that cause disproportionate pediatric impact (e.g., respiratory syncytial virus, RSV). In our prior work, we showed the impact of these surges on children and health systems by surfacing information about the trajectories of pediatric COVID-19 hospitalization rates and severity distributions as well as viral co-infection on a public dashboard and regularly presented these data to federal decision-makers. Novel variants are likely to develop and spread. A more virulent and vaccine-resistant variant could trigger a new surge in cases. Such a surge could again put pediatric health system function at risk and present new pediatric clinical phenotypes of COVID-19. The overall objective of this Supplement is to make information about the trajectories of pediatric COVID-19 hospitalization rates and disease severity and unique pediatric COVID-19 clinical phenotypes readily available for national-level decision-making. We will further develop computational pipelines to analyze the trajectories of pediatric COVID-19 hospitalization rates and disease severity and extend our interactive pediatric COVID-19 severity dashboard for near-real-time tracking of the impact of the SARS-CoV-2 pandemic. To do this, we will leverage the National COVID Cohort Collaborative (N3C), a resource developed with funding from the National Center for Advancing Translational Sciences (NCATS). N3C aggregates electronic health record (EHR) data from more than 70 U.S. centers. In our prior work, we have demonstrated our ability to analyze the granular multicenter EHR data in N3C, leverage state-of-the-art computational resources on the N3C platform, and implement analytic techniques similar to those in this proposal. We will use these rich EHR data in N3C to accomplish the following specific aim: 1A) maintain, extend, and disseminate an interactive pediatric COVID-19 dashboard and 1B) monitor for and report on emergent pediatric COVID-19 clinical phenotypes. We have assembled an investigative team with a successful track record in the field and will work in partnership with NIH leadership to address this national and global health priority. We expect this Supplement to have a powerful and sustained impact on COVID-19 policymaking and the outcomes of affected children by decreasing the likelihood of overwhelmed U.S. pediatric health systems.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tellen Bennett其他文献

Tellen Bennett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tellen Bennett', 18)}}的其他基金

Novel Pediatric Sepsis Criteria and Clinical Decision Support Tools
新型儿科败血症标准和临床决策支持工具
  • 批准号:
    10280004
  • 财政年份:
    2021
  • 资助金额:
    $ 23.76万
  • 项目类别:
Novel Pediatric Sepsis Criteria and Clinical Decision Support Tools
新型儿科败血症标准和临床决策支持工具
  • 批准号:
    10478249
  • 财政年份:
    2021
  • 资助金额:
    $ 23.76万
  • 项目类别:
Novel Pediatric Sepsis Criteria and Clinical Decision Support Tools
新型儿科败血症标准和临床决策支持工具
  • 批准号:
    10684927
  • 财政年份:
    2021
  • 资助金额:
    $ 23.76万
  • 项目类别:
Archiving Common Data Element-Harmonized Pediatric Traumatic Brain Injury Data and Metadata
归档通用数据元素 - 协调的儿科创伤性脑损伤数据和元数据
  • 批准号:
    9789058
  • 财政年份:
    2018
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    8579363
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    8695424
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    9049521
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    9263010
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    8857351
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:
Effectiveness of ICP Monitoring in Pediatric Traumatic Brain Injury
ICP 监测在小儿创伤性脑损伤中的有效性
  • 批准号:
    8847755
  • 财政年份:
    2013
  • 资助金额:
    $ 23.76万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了